Science

Amy Moore: Biomarker testing can help identify actionable mutations in patients with squamous NSCLC

Amy Moore/LinkedIn

Jan 20, 2025, 16:03

Amy Moore: Biomarker testing can help identify actionable mutations in patients with squamous NSCLC

Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a post on LinkedIn about a recent paper by Joshua Reuss et al. published in Lung Cancer Journal:

“Biomarker testing can help identify actionable mutations in patients with squamous NSCLC, especially in those without a history of smoking. Testing is not performed consistently in this population.

“Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking”

Authors: Joshua Reuss, Jacob Zaemes, Nishant Gandhi, Phillip Walker, Sandip Patel, Joanne Xiu, Charu Aggarwal, Ari Vanderwalde, Suresh Ramalingam, Balazs Halmos, Stephen Liu.

More posts featuring Amy Moore.

Amy Moore Ari Vanderwalde Balazs Halmos biomarker testing cancer Charu Aggarwal Jacob Zaemes Joanne Xiu Joshua Reuss Nishant Gandhi non small cell lung cancer NSCLC OncoDaily Oncology Phillip Walker Sandip Patel Stephen Liu Suresh Ramalingam

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer